Market Cap 202.40B
Revenue (ttm) 46.79B
Net Income (ttm) 15.51B
EPS (ttm) N/A
PE Ratio 11.35
Forward PE 13.20
Profit Margin 33.14%
Debt to Equity Ratio 0.72
Volume 13,602,484
Avg Vol 11,867,816
Day's Range N/A - N/A
Shares Out 4.47B
Stochastic %K 5%
Beta 0.76
Analysts Hold
Price Target $46.76

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 45 44 44 88 88
Address:
Novo Alle 1, Bagsvaerd, Denmark
fiiked
fiiked Sep. 3 at 12:06 AM
$NVO wake me up when reaches 50+
0 · Reply
SniperPro
SniperPro Sep. 2 at 8:12 PM
$LXRX $NVO $VTRS $PFE $MRK 🤔 Who’s going to be Lexicon’s next partner? With Lexicon Pharmaceuticals building momentum and its pipeline attracting attention, the big question is: who could be next to partner with Lex? Could it be $NVO $VTRS $PFE or $MRK ? The right partnership could be a major catalyst for $LXRX. 👀 Speculation for now—but it’s definitely worth watching closely. Who do you think is next? 🔥 Why are shorts covering? What do they know? TICK TOCK!!!!
0 · Reply
JacoI3
JacoI3 Sep. 2 at 8:07 PM
$NVO Why did it hold gains?
1 · Reply
just10c
just10c Sep. 2 at 7:38 PM
$NVO 63.09 ─────────────── 🎯 Major upside target 53.90 ─────────────── 🎯 Resistance 51.52 ─────────────── 🚨 Major breakout level 48.43 ─────────────── 🚨 Immediate resistance 46.84 ← CURRENT 46.05 ─────────────── 🟢 Immediate support 42.96 ─────────────── 🔥 Major support / breakdown level 40.58 ─────────────── 🎯 Bear target 37.49 ─────────────── 🎯 Bear target 32.38 ─────────────── 🎯 Major downside target
0 · Reply
Cap_00
Cap_00 Sep. 2 at 7:08 PM
$NVO They needs to start buying like LLY..
1 · Reply
Jtlo
Jtlo Sep. 2 at 7:04 PM
$NVO i don't even want to jinx it
0 · Reply
Hooooooold
Hooooooold Sep. 2 at 6:59 PM
$NVO oh yea baby keep it going
1 · Reply
Cap_00
Cap_00 Sep. 2 at 6:29 PM
$NVO PE is just 11.. lowest of all big pharma.. historically, it's ~30. Recent failures haven't help but at this multiple, they have the biggest upside..
0 · Reply
Fizz26
Fizz26 Sep. 2 at 6:18 PM
$DJIA $NVO go long
0 · Reply
Smoka416
Smoka416 Sep. 2 at 6:10 PM
$NVO Screaming buy
0 · Reply
Latest News on NVO
Novo Nordisk launches Wegovy weight-loss pill in Germany

Tue, 01 Sep 2026 04:55:30 -0400 - 1 day ago

Novo Nordisk launches Wegovy weight-loss pill in Germany


Call of the Day: Deutsche downgrades Novo Nordisk

2026-08-27T21:48:04.000Z - 6 days ago

Call of the Day: Deutsche downgrades Novo Nordisk


Novo Nordisk's Weight Management Pill Approved in China

2026-08-27T10:12:17.000Z - 6 days ago

Novo Nordisk's Weight Management Pill Approved in China


Novo Nordisk downgraded to Sell from Hold at Deutsche Bank

2026-08-27T08:45:28.000Z - 6 days ago

Novo Nordisk downgraded to Sell from Hold at Deutsche Bank


Novo Nordisk downgraded to Hold from Buy at Berenberg

2026-08-17T10:23:20.000Z - 16 days ago

Novo Nordisk downgraded to Hold from Buy at Berenberg


Novo Nordisk Escalates Weight-Loss War With Eli Lilly

2026-08-13T17:32:27.000Z - 20 days ago

Novo Nordisk Escalates Weight-Loss War With Eli Lilly


Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Thu, 13 Aug 2026 13:00:00 -0400 - 20 days ago

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?


Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)

2026-08-13T14:52:11.000Z - 20 days ago

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)

LLY


Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

Aug 12, 2026, 8:04 PM EDT - 21 days ago

Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

NVO


Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

2026-08-12T23:46:55.000Z - 21 days ago

Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer


Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

2026-08-12T14:56:50.000Z - 21 days ago

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market


PHARMA BETS: CEO turns to AI for next-generation drugs

Aug 12, 2026, 10:30 AM EDT - 21 days ago

PHARMA BETS: CEO turns to AI for next-generation drugs

NVO


Novo Nordisk Earnings Call Transcript: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 4 weeks ago

Novo Nordisk Earnings Call Transcript: Q2 2026


Novo Nordisk Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 4 weeks ago

Novo Nordisk Quarterly report: Q2 2026


Novo Nordisk Slides: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 4 weeks ago

Novo Nordisk Slides: Q2 2026


Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

Aug 4, 2026, 2:16 PM EDT - 4 weeks ago

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

NVO


Novo Nordisk's Q2 profit beats forecasts, raises outlook

Aug 4, 2026, 12:41 PM EDT - 4 weeks ago

Novo Nordisk's Q2 profit beats forecasts, raises outlook

NVO


Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial

Jul 31, 2026, 10:56 AM EDT - 4 weeks ago

Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial

NVO


Novo Nordisk shares dive 9% after heart medicine fails trial

Jul 31, 2026, 7:43 AM EDT - 4 weeks ago

Novo Nordisk shares dive 9% after heart medicine fails trial

NVO


Weight loss drugs linked to increase risk of hair loss

Jul 22, 2026, 8:57 PM EDT - 5 weeks ago

Weight loss drugs linked to increase risk of hair loss

LLY NVO


Hair loss with GLP-1 drugs is rare, but real, studies find

Jul 22, 2026, 6:31 PM EDT - 6 weeks ago

Hair loss with GLP-1 drugs is rare, but real, studies find

AZN LLY NVO


Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

Jul 21, 2026, 10:29 AM EDT - 6 weeks ago

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

LLY NVO


fiiked
fiiked Sep. 3 at 12:06 AM
$NVO wake me up when reaches 50+
0 · Reply
SniperPro
SniperPro Sep. 2 at 8:12 PM
$LXRX $NVO $VTRS $PFE $MRK 🤔 Who’s going to be Lexicon’s next partner? With Lexicon Pharmaceuticals building momentum and its pipeline attracting attention, the big question is: who could be next to partner with Lex? Could it be $NVO $VTRS $PFE or $MRK ? The right partnership could be a major catalyst for $LXRX. 👀 Speculation for now—but it’s definitely worth watching closely. Who do you think is next? 🔥 Why are shorts covering? What do they know? TICK TOCK!!!!
0 · Reply
JacoI3
JacoI3 Sep. 2 at 8:07 PM
$NVO Why did it hold gains?
1 · Reply
just10c
just10c Sep. 2 at 7:38 PM
$NVO 63.09 ─────────────── 🎯 Major upside target 53.90 ─────────────── 🎯 Resistance 51.52 ─────────────── 🚨 Major breakout level 48.43 ─────────────── 🚨 Immediate resistance 46.84 ← CURRENT 46.05 ─────────────── 🟢 Immediate support 42.96 ─────────────── 🔥 Major support / breakdown level 40.58 ─────────────── 🎯 Bear target 37.49 ─────────────── 🎯 Bear target 32.38 ─────────────── 🎯 Major downside target
0 · Reply
Cap_00
Cap_00 Sep. 2 at 7:08 PM
$NVO They needs to start buying like LLY..
1 · Reply
Jtlo
Jtlo Sep. 2 at 7:04 PM
$NVO i don't even want to jinx it
0 · Reply
Hooooooold
Hooooooold Sep. 2 at 6:59 PM
$NVO oh yea baby keep it going
1 · Reply
Cap_00
Cap_00 Sep. 2 at 6:29 PM
$NVO PE is just 11.. lowest of all big pharma.. historically, it's ~30. Recent failures haven't help but at this multiple, they have the biggest upside..
0 · Reply
Fizz26
Fizz26 Sep. 2 at 6:18 PM
$DJIA $NVO go long
0 · Reply
Smoka416
Smoka416 Sep. 2 at 6:10 PM
$NVO Screaming buy
0 · Reply
ContrarianLife
ContrarianLife Sep. 2 at 6:08 PM
$NVO Go on ahead and breakout of this stage 1 recovery. Stage 2 is LATE.
0 · Reply
biolover
biolover Sep. 2 at 3:46 PM
$VKTX the stupidity is $NVO owners are jealous and hate Viking although the later is only chance of novo competing with Lilly or anyone else long term. I hope BL never makes a deal with novo and if he does not do it with < $40 B. ( i doubt he will sell < $30 B to anyone if the Vanqyish efficacy is vetter than TZP … all depends on that. )
2 · Reply
Makingmillions192
Makingmillions192 Sep. 2 at 3:07 PM
$LEXX is coiling for a MASSIVE breakout! 🚀🔥 Key catalysts aligned: ✅ $2.6M USD cash tax rebate secured = NO short-term dilution! 💰 ✅ Debt-free balance sheet with runway deep into 2027 🛡️ ✅ Resistance cleared! $12.00–$12.30 converted to solid support 🎯 ✅ Next technical price target: $13.50 – $15.00+ 📈 ✅ Tight 1.65M share float = low liquidity on the ask, ripe for a squeeze 🩳💥 🔥 BIGGEST CATALYST AHEAD: Human Study #7 GLP-1 top-line PK results dropping soon! Head-to-head steady-state data vs. Wegovy® tablets could drive a major revaluation before commercial deals even hit. Don't sleep on this coiling spring! 💎🙌 LFG! $LLY $NVO $RANI $VIK #Biotech #GLP1 #DehydraTECH
0 · Reply
Oldmoneycashhoney
Oldmoneycashhoney Sep. 2 at 2:29 PM
$NVO buy or sell?
2 · Reply
LoveRetailFroth
LoveRetailFroth Sep. 2 at 2:20 PM
$AMLX 🤔 I am thinking what Phase 2 asset this company can buy in the Endo space with that 800 Million war chest. Yeah they could themselves bought out. Exciting times. Let the bidding wars begin☕️ $LLY $NVO
0 · Reply
Alexhere
Alexhere Sep. 2 at 2:17 PM
$NVO fair value $110
0 · Reply
Alexhere
Alexhere Sep. 2 at 2:15 PM
$NVO Novo Nordisk (CPSE:NOVO B) is back in focus after launching its Wegovy pill in Germany, the first EU market to offer the oral weight loss treatment, putting its GLP-1 obesity ambitions under closer investor scrutiny. Most Popular Narrative: 65.5% Undervalued According to the most followed narrative on Novo Nordisk, a fair value of DKK851.04 sits well above the last close of DKK293.75, which puts the current share price firmly in the discount zone and makes the assumptions behind that gap worth understanding.
0 · Reply
Alexhere
Alexhere Sep. 2 at 2:13 PM
$NVO https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-190955830.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIH3PtS1kcAjImMaWgogAGnW9mPTIaWhvZDZ_gPr4Zurrc7JLLOjvIfYBVv6oNKxMVBP-KwRevWAHY-2FlrYTUOSM5Zh3x4QGIBuip8tBDoKaTNY4bRmqlpPMgqt4m4WJ6--OGpBrakKCGZlN1lx1DtfZXRm23OXQjPIxkYMlzSj
0 · Reply
Niuniucat
Niuniucat Sep. 2 at 2:10 PM
$NVO it’s a $75 stock
2 · Reply
JacoI3
JacoI3 Sep. 2 at 1:59 PM
$NVO Whoa what?
1 · Reply
BubbleBanker
BubbleBanker Sep. 2 at 1:52 PM
$NVO let’s see that 5% today
0 · Reply
Oldmoneycashhoney
Oldmoneycashhoney Sep. 2 at 1:49 PM
$NVO why?
0 · Reply